findmyKOL
Clinical trialNCT07070466RecruitingPhase 2Interventional

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

SponsorMassachusetts General HospitalEnrollment40Esophagus CancerStomach CancerStomach Cancer Stage IV
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ucla

    Santa Monica, California, United States

    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FluorouracilIvonescimabLeucovorinOxaliplatin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Oct 2025
Primary completion
1 Dec 2026
Completion
1 Sept 2028
Last update posted
6 Mar 2026
Registered enrollment
40
Registry id
NCT07070466
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.